Originally posted by Kung Wu
View Post
Study: Vaccines Strongly Protect Those 65-Plus Against Hospitalization
New findings of a recent study of hospital data found that the three available COVID-19 vaccines in the U.S. were highly effective in preventing severe illness and hospitalization in adults 65 years of age or older.
Researchers monitored COVID-19 patients 65 and older between February 1 and April 30. According to the study, the two-dose Pfizer-BioNTech and Moderna vaccines reduced the risk of hospitalization by 96 percent in adults 65-74 years old. The single-dose Johnson & Johnson vaccine lowered the risk of hospitalization by 84 percent for adults of the same age range. A previous study released by the CDC reported similar results.
“In this analysis of 7,280 laboratory-confirmed COVID-19 cases among hospitalized adults aged 65 or older, all three COVID-19 vaccine products currently authorized for use in the United States had high effectiveness in preventing COVID-19–associated hospitalizations,” states the CDC.
These findings are consistent with estimates from other observational studies of the mRNA vaccines from Pfizer and Moderna, and provide an early estimate of the effectiveness of Johnson & Johnson vaccine in preventing COVID-19–associated hospitalization. The CDC study covered a period of time before the delta variant become the dominant COVID-19 strain. However, other studies since then have shown that all three vaccines continue to provide robust protection against severe illness against the more transmissible delta variant.
The data included in the study’s analysis were from: California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.
New findings of a recent study of hospital data found that the three available COVID-19 vaccines in the U.S. were highly effective in preventing severe illness and hospitalization in adults 65 years of age or older.
Researchers monitored COVID-19 patients 65 and older between February 1 and April 30. According to the study, the two-dose Pfizer-BioNTech and Moderna vaccines reduced the risk of hospitalization by 96 percent in adults 65-74 years old. The single-dose Johnson & Johnson vaccine lowered the risk of hospitalization by 84 percent for adults of the same age range. A previous study released by the CDC reported similar results.
“In this analysis of 7,280 laboratory-confirmed COVID-19 cases among hospitalized adults aged 65 or older, all three COVID-19 vaccine products currently authorized for use in the United States had high effectiveness in preventing COVID-19–associated hospitalizations,” states the CDC.
These findings are consistent with estimates from other observational studies of the mRNA vaccines from Pfizer and Moderna, and provide an early estimate of the effectiveness of Johnson & Johnson vaccine in preventing COVID-19–associated hospitalization. The CDC study covered a period of time before the delta variant become the dominant COVID-19 strain. However, other studies since then have shown that all three vaccines continue to provide robust protection against severe illness against the more transmissible delta variant.
The data included in the study’s analysis were from: California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.
71% sucks. Particularly when a study uses a cherry-picked subset of the population: healthcare workers who will be on average healthier w/ stronger immune systems than the 65-plus group.
Comment